We have a drug that could transform HIV prevention. So why can’t millions get it? A twice-yearly injection could revolutionise HIV prevention. But who gets access raises bigger questions about public money, pharmaceutical power, drug prices and shrinking global health funding. Al Jazeera’s Mikail Malik looks at the fight over access.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.